SCHEMBL2696967

SCHEMBL2696967

O=C1OC[C@H](O)[C@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2696971 1.00
SCHEMBL818248 1.00
SCHEMBL5950880 1.00
SCHEMBL3927878 1.00
SCHEMBL19363012 1.00
SCHEMBL2466059 0.84 LMNA (0.35)
SCHEMBL2931003 0.84 LMNA (0.35)
SCHEMBL15858 0.84 LMNA (0.40)
SCHEMBL15630 0.84 LMNA (0.40)
SCHEMBL21698544 0.84 LMNA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594520-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2025-08-06 EP claimed
CN-119916028-A Marker related to progressive freezing syndrome and kit thereof 厦门市迈理奥科技有限公司 2025-05-02 CN claimed
WO-2024069235-A2 COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS Sixfold Bioscience Ltd. (GB) 2024-04-04 WO claimed
CN-116806263-A Method for producing 2, 4-dihydroxybutyric acid or L-threonine using microbial metabolic pathway 德累斯顿科技大学 2023-09-26 CN claimed
US-12447118-B2 Hair treatment compositions CONOPCO, INC. (US) 2025-10-21 US disclosed
CN-119916028-A Marker related to progressive freezing syndrome and kit thereof 厦门市迈理奥科技有限公司 2025-05-02 CN disclosed
EP-4281572-A1 PROCESS FOR PREPARING 2,4-DIHYDROXYBUTYRATE OR L-THREONINE USING A MICROBIAL METABOLIC PATHWAY Technische Universität Dresden (DE) 2023-11-29 EP disclosed
CN-116806263-A Method for producing 2, 4-dihydroxybutyric acid or L-threonine using microbial metabolic pathway 德累斯顿科技大学 2023-09-26 CN disclosed
WO-2023158255-A1 COMPOUND FOR ELECTROLYTE, COMPOUND FOR ELECTROLYTE ADDITIVE, ELECTROLYTE MATERIAL, ELECTROLYTE ADDITIVE, ELECTROLYTE FOR SECONDARY BATTERY, AND SECONDARY BATTERY 주식회사 렉쎌 2023-08-24 WO disclosed
US-20230159929-A1 MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF ALIGOS THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230159929-A1 MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF ALIGOS THERAPEUTICS, INC. 2023-05-25 US disclosed
CN-110996886-B Hair composition for wound treatment 联合利华知识产权控股有限公司 2023-03-28 CN disclosed
US-20070185062-A1 Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2007-08-09 US disclosed
US-20070185062-A1 Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2007-08-09 US disclosed
EP-1750572-A2 METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF Stressmeter A/S (DK) 2007-02-14 EP disclosed
EP-1720890-A2 PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION K.U.Leuven Research & Development (BE) 2006-11-15 EP disclosed
US-20060111347-A1 Substituted sulfones and methods of use AMGEN INC. (US) 2006-05-25 US disclosed
WO-2006041888-A2 SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 2006-04-20 WO disclosed
WO-2005084529-A2 METHOD OF DETERMINING THE SYMPATHETIC TONE AND SYSTEM FOR MEASUREMENT THEREOF STRESSMETER A/S (DK) 2005-09-15 WO disclosed
WO-2005085268-A2 PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2005-09-15 WO disclosed